ASP-2535

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H18N6O
Molecular Weight	382.4179
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC(C)C1=NN=C(N1C2=CC=CC3=NON=C23)C4=CC=C(N=C4)C5=CC=CC=C5

InChI

InChIKey=FQGLDGKVKDPVLO-UHFFFAOYSA-N

InChI=1S/C22H18N6O/c1-14(2)21-24-25-22(28(21)19-10-6-9-18-20(19)27-29-26-18)16-11-12-17(23-13-16)15-7-4-3-5-8-15/h3-14H,1-2H3

HIDE SMILES / InChI

Molecular Formula	C22H18N6O
Molecular Weight	382.4179
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

ASP-2535 is a glycine transporter-1 (GlyT1) inhibitor which was developed by Astellas Pharma for the treatment of Schizophrenia and Alzheimer's disease. Although ASP-2535 was shown to improve cognitive impairment in animal models, it is no longer in the company pipeline.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glycine transporter 1 7	Inhibitor 8,297		92.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alzheimer’s disease 272	Primary		Preclinical	Unknown
Schizophrenia 298	Primary		Preclinical	Unknown

PubMed

Show entries

Title	Date	PubMed
A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.	2012 Jun 15	22542656

Showing 1 to 1 of 1 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

Rats were given ASP-2535 at a dose of 0.1-3 mg/kg

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical
Record UNII	6627LI8F9K
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

ASP-2535

Common Name

English

2,1,3-BENZOXADIAZOLE, 4-(3-(1-METHYLETHYL)-5-(6-PHENYL-3-PYRIDINYL)-4H-1,2,4-TRIAZOL-4-YL)-

Systematic Name

English

4-(3-(1-METHYLETHYL)-5-(6-PHENYL-3-PYRIDINYL)-4H-1,2,4-TRIAZOL-4-YL)-2,1,3-BENZOXADIAZOLE

Systematic Name

English

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Code System

Code

Type

Description

PUBCHEM

9800113

PRIMARY

FDA UNII

6627LI8F9K

PRIMARY

CAS

374886-51-8

PRIMARY

MANUFACTURER PRODUCT INFORMATION

ASP-2535

PRIMARY

ASP 2535: Cat. No. 5308Biological Activity: Potent and selective GlyT1 inhibitor (IC50 = 92 nM). Exhibits 50-fold selectivity over GlyT2. Attenuates MK 801-induced working memory deficits and PCP-induced visual learning deficits in mice. Orally available and brain penetrant.

SMS_ID

300000042369

PRIMARY

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Related Record

Type

Details


					Q7GH5KAP6O

GLYCINE TRANSPORTER-1

TARGET -> INHIBITOR

Qualification:

IC50

Amount:

92 NANOMOLAR (average)

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					6627LI8F9K

ASP-2535

ACTIVE MOIETY

Comments:

Originator: Astellas Pharma; Class: Antidementia, Antipsychotic; Highest Development Phases: Discontinued for Alzheimer's disease, Schizophrenia; Most Recent Events: 29 May 2009 Discontinued - Phase-I for Schizophrenia in Japan (PO), 29 May 2009 Discontinued - Phase-I for Alzheimer's disease in Japan (PO), 29 Aug 2008 Phase-I clinical trials in Schizophrenia in Japan (PO)

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

Description<div class="info-popup-container"><div><span class="pop-sub-key ">Sources:&nbsp;</span><span class="pop-sub-val"><span class="ext-link"><a target="_self" href="https://www.ncbi.nlm.nih.gov/pubmed/22542656">https://www.ncbi.nlm.nih.gov/pubmed/22542656</a></span></span></div></div>

CNS Activity

Originator

Approval Year

Targets

Conditions

PubMed

Patents

Sample Use Guides

Description